List of Excipients in Branded Drug NORELGESTROMIN AND ETHINYL ESTRADIOL

Generic Drugs Containing NORELGESTROMIN AND ETHINYL ESTRADIOL

Company	Ingredient	NDC	Excipient
Zydus Pharmaceuticals USA Inc	norelgestromin and ethinyl estradiol	70710-1190	CROSPOVIDONE
Zydus Pharmaceuticals USA Inc	norelgestromin and ethinyl estradiol	70710-1190	LAURYL LACTATE
Zydus Lifesciences Limited	norelgestromin and ethinyl estradiol	70771-1777	CROSPOVIDONE

What are the Most Frequently-Used Excipients in NORELGESTROMIN AND ETHINYL ESTRADIOL?

# Of NDCs	Excipient
2	CROSPOVIDONE
2	LAURYL LACTATE

Excipient Strategy and Commercial Opportunities for Norelgestromin and Ethinyl Estradiol Transdermal Patches

Last updated: August 9, 2026

Norelgestromin and ethinyl estradiol is a once-weekly combined hormonal contraceptive delivered through a drug-in-adhesive transdermal patch. The commercial opportunity is concentrated in patch performance rather than new active-ingredient protection. Key value drivers are adhesion, controlled drug release, skin tolerability, reduced patch size, manufacturing reliability, and differentiated delivery systems.

The reference product, Ortho Evra, established the product category. Xulane, marketed by Mylan and later associated with Viatris, is the principal U.S. generic product. The product contains norelgestromin and ethinyl estradiol and is applied weekly for three consecutive weeks, followed by one patch-free week. FDA labeling identifies a nominal delivery rate of approximately 150 micrograms of norelgestromin and 35 micrograms of ethinyl estradiol per day.[1]

What excipients are used in norelgestromin and ethinyl estradiol patches?

The patch uses a multilayer transdermal system rather than a conventional tablet excipient platform. The functional excipients are part of the adhesive matrix, backing layer, release liner, and protective packaging.

Xulane patch composition

FDA labeling describes Xulane as a three-layer system:

Patch component	Primary function	Commercial relevance
Backing layer	Protects the drug matrix and controls environmental exposure	Affects flexibility, moisture transmission, and patch durability
Drug-in-adhesive matrix	Contains the active ingredients and maintains skin contact	Determines release rate, adhesion, drug loading, and skin tolerability
Release liner	Protects the adhesive before application	Controls stability, peel performance, and user handling

The inactive ingredients identified for Xulane include polyisobutylene, polybutene, crospovidone, polyester materials, and siliconized release-liner materials, according to the product labeling and product-description information.[1,2]

Polyisobutylene and polybutene provide pressure-sensitive adhesive functionality. They also act as the continuous polymer phase through which the hormones diffuse. Crospovidone is used in the adhesive matrix and can influence drug dispersion, crystallization behavior, and matrix structure. Polyester materials provide mechanical support in the backing and liner components.

The formulation is therefore a device-drug combination. An excipient change can affect not only chemical stability but also peel adhesion, shear resistance, drug flux, residual drug, skin irritation, and manufacturing process control.

How does the excipient system control drug release?

The patch releases norelgestromin and ethinyl estradiol through a polymeric adhesive matrix placed directly on the skin. Drug delivery depends on the interaction of five variables:

1. Drug solubility in the adhesive polymer.
2. Drug diffusion through the matrix.
3. Partitioning from the adhesive into the stratum corneum.
4. Skin permeability at the application site.
5. Adhesive contact over the full seven-day wear period.

Norelgestromin and ethinyl estradiol have different physicochemical properties. Their relative solubility and diffusivity in the polymer matrix must be balanced to prevent one active ingredient from becoming the release-rate limiter. A formulation that improves total flux but changes the norelgestromin-to-ethinyl estradiol exposure ratio could create a regulatory problem even if the overall delivery rate remains acceptable.

Critical excipient attributes

The highest-value excipient attributes are:

• Consistent molecular-weight distribution in polyisobutylene.
• Controlled viscosity and tack in polybutene.
• Low extractables and leachables.
• Low residual solvent content.
• Compatibility with both steroidal actives.
• Resistance to cold flow during storage.
• Stable adhesion under heat, humidity, sweat, and mechanical stress.
• Minimal skin sensitization and irritation.
• Controlled drug crystallization during shelf life.

The excipient strategy should begin with a design-space assessment that links polymer grade, drug loading, coating thickness, drying conditions, and adhesive performance. Direct substitution of a nominally equivalent adhesive polymer can change drug release enough to require a new clinical or comparative-performance package.

What formulation patents protect norelgestromin and ethinyl estradiol patches?

The relevant intellectual property is likely to center on transdermal delivery architecture, adhesive composition, steroid release control, patch construction, and manufacturing processes rather than composition-of-matter protection for the active ingredients.

Patent categories with commercial value

Patent category	Protectable subject matter	Competitive value
Drug-in-adhesive matrix	Polymer ratios, drug loading, matrix uniformity	High for formulation differentiation
Adhesive composition	Polyisobutylene, polybutene, tackifiers, stabilizers	High where adhesion or tolerability improves
Multilayer construction	Backing, matrix, liner, edge design	Moderate to high
Manufacturing process	Coating, drying, lamination, die cutting, packaging	High as a process barrier
Controlled delivery	Release profile and hormone flux	High if linked to clinical performance
Skin interface	Permeation enhancers and irritation-reduction systems	High but development-intensive
Packaging	Moisture and oxygen protection	Moderate

The original product’s core patent estate is mature. The commercial question is not whether the original active ingredients remain patent protected. It is whether a new formulation, patch geometry, adhesive system, or manufacturing process can support enforceable patent claims and regulatory differentiation.

A current Orange Book review should distinguish patents listed for an approved product from expired historical patents and from unlisted formulation or device patents. FDA’s Orange Book identifies patents and regulatory exclusivities submitted for listed drug products, but it does not capture every potentially relevant patent covering a delivery platform or manufacturing process.[3]

When does norelgestromin and ethinyl estradiol lose exclusivity?

The active ingredients are long-established and do not have meaningful new chemical entity exclusivity. U.S. market access is therefore primarily governed by generic-drug competition, product-specific patents, regulatory exclusivity, and manufacturing capability.

Exclusivity timeline

Milestone	Commercial implication
Original Ortho Evra approval	Established the reference transdermal contraceptive
Generic approval of norelgestromin/ethinyl estradiol patches	Opened ANDA-based competition
Expiration of historical product patents	Reduced barriers to generic entry
Current market	Competition depends on approved patch equivalence, supply, and payer access
Future reformulations	May obtain new patents but do not automatically receive new-chemical-entity exclusivity

For a mature transdermal product, market exclusivity can persist commercially after patent expiry because of formulation complexity. A generic sponsor must demonstrate pharmaceutical equivalence and bioequivalence through a technically demanding patch platform. Failure can arise from poor adhesion, divergent pharmacokinetics, inconsistent drug content, or manufacturing variability.

What is the Orange Book status of norelgestromin and ethinyl estradiol?

Xulane is an FDA-approved prescription transdermal contraceptive and is subject to the Orange Book framework applicable to listed drug products.[2,3] The Orange Book status should be assessed by product, strength, dosage form, and current patent listing.

The key regulatory distinction is between:

• Listed patents that can support a Paragraph IV certification.
• Expired patents that no longer block approval.
• Unlisted patents that may still be relevant to infringement litigation.
• Device, process, or formulation patents that may not appear in the same manner as classic active-ingredient patents.

For commercial diligence, an Orange Book search should be paired with FDA approval letters, patent-family records, and litigation databases. A Paragraph IV challenge to a listed patent can trigger a 30-month stay in certain circumstances under the Hatch-Waxman framework, although the precise effect depends on the timing and status of the litigation.[4]

Which companies are challenging or competing with norelgestromin and ethinyl estradiol patches?

Competition exists at three levels: generic norelgestromin/ethinyl estradiol patches, alternative hormonal patches, and non-patch contraceptive products.

Generic and branded competition

Xulane is associated with the norelgestromin/ethinyl estradiol patch market in the United States. The original branded product was Ortho Evra. Other hormonal patches, such as Twirla, use a different active-ingredient combination, levonorgestrel and ethinyl estradiol, and are not therapeutically identical substitutes for purposes of generic approval.[5]

Competitive products include:

• Generic norelgestromin/ethinyl estradiol patches.
• Levonorgestrel/ethinyl estradiol patches.
• Combined oral contraceptives.
• Vaginal rings.
• Long-acting reversible contraceptives.
• Progestin-only implants, injections, and intrauterine systems.

The patch’s commercial advantages are weekly dosing and avoidance of daily oral administration. Its disadvantages include visible application, adhesion failures, skin reactions, and higher systemic ethinyl estradiol exposure than some oral contraceptive regimens. FDA labeling warns that ethinyl estradiol exposure with the patch is higher than exposure associated with a typical 35-microgram ethinyl estradiol oral contraceptive, although exposure comparisons depend on the pharmacokinetic metric used.[1]

What formulation opportunities exist for norelgestromin and ethinyl estradiol?

The strongest opportunities are incremental improvements that preserve the established weekly delivery profile.

1. Improved adhesion

Adhesion is the central commercial vulnerability. Development targets include:

• Better adhesion during bathing, exercise, and sweating.
• Lower edge lift.
• Reduced transfer of adhesive residue.
• Improved adhesion across skin types and application sites.
• Lower sensitivity to sebum and moisture.
• Better adhesion without higher peel force during removal.

Potential approaches include modified polyisobutylene/polybutene ratios, alternative tackifier systems, surface-patterned adhesive layers, and engineered edge zones. Any change must be evaluated for drug migration and skin irritation.

2. Smaller patch size

A smaller patch could improve discretion, comfort, and acceptance. The principal technical challenge is maintaining weekly drug flux while reducing total area. This may require higher drug activity, improved skin partitioning, a more permeable adhesive matrix, or a controlled permeation enhancer.

A smaller patch can also increase local drug concentration and skin exposure. The development package should include irritation, sensitization, adhesion, residual drug, and pharmacokinetic testing.

3. Lower ethinyl estradiol exposure

A reduced-ethinyl-estradiol patch could address a recognized product concern. The formulation target would be a lower systemic estrogen exposure while maintaining contraceptive efficacy and acceptable cycle control.

This strategy carries a high regulatory burden. A lower exposure profile can affect bleeding patterns, ovulation suppression, and efficacy. The product may no longer qualify as a simple reformulation if the clinical pharmacology and therapeutic profile materially change.

4. Improved skin tolerability

Skin tolerability can be improved by reducing residual monomers, low-molecular-weight adhesive fractions, extractables, and irritating formulation components. A softer adhesive may improve comfort but reduce shear resistance. A more aggressive adhesive may reduce detachment but increase erythema and removal pain.

The most valuable formulation is not the one with the highest initial tack. It is the one that maintains sufficient adhesion for seven days with limited skin reaction.

5. Longer wear duration

A two-week or monthly patch would create a strong commercial distinction, but it would require a major redesign of drug loading, matrix stability, adhesion, packaging, and clinical use instructions. The risk of dose drift over an extended wear period is substantial.

A monthly patch could compete more directly with vaginal rings and long-acting methods. It would also create a new adherence profile and likely require clinical studies beyond standard generic-equivalence testing.

What regulatory pathway applies to new patch formulations?

A conventional generic norelgestromin/ethinyl estradiol patch generally proceeds through an ANDA if it matches the reference product in active ingredients, dosage form, route, strength, and relevant performance characteristics.[4]

A materially redesigned patch may require a different pathway or supplemental approval strategy. Regulatory risk increases when the product has:

• A different adhesive matrix.
• A different patch size.
• A new permeation enhancer.
• A changed release profile.
• A different wear interval.
• A new application site.
• A materially different pharmacokinetic profile.
• New clinical claims.

FDA assessment can include drug content uniformity, in vitro release, adhesion, peel, shear, residual drug, skin irritation, sensitization, pharmacokinetics, and comparative clinical performance. FDA’s transdermal product guidance emphasizes the relationship between formulation, adhesion, permeation, and product performance.[6]

What manufacturing and intellectual-property barriers affect commercial entry?

Manufacturing is a material barrier even after core patents expire. Key process steps include:

1. Steroid weighing and blending.
2. Adhesive compounding.
3. Coating at controlled thickness.
4. Solvent removal or drying.
5. Lamination with backing and release liner.
6. Die cutting.
7. Individual pouching.
8. Stability testing under heat and humidity.

Common failure modes include dose nonuniformity, adhesive residue, edge lift, liner separation, active crystallization, liner-transfer defects, and pouch leakage.

Manufacturing patents can protect coating methods, matrix preparation, patch geometry, and packaging. Trade secrets may be more important than patents for process controls and scale-up parameters. A reliable supplier network for medical-grade adhesive polymers and coated substrates is also a competitive asset.

How strong is the patent estate for new excipient strategies?

Patent strength depends on claim specificity and design-around difficulty.

Stronger claim types

• Narrow polymer-ratio claims linked to a defined release profile.
• Adhesive compositions with measurable peel and shear properties.
• Patch constructions that solve edge-lift or moisture problems.
• Manufacturing claims that improve content uniformity.
• Formulation claims supported by comparative pharmacokinetic or adhesion data.

Weaker claim types

• Broad use of conventional pressure-sensitive adhesives.
• Generic claims to weekly transdermal contraception.
• Claims defined only by routine excipient substitution.
• Claims lacking a measurable performance limitation.
• Claims that can be avoided by changing polymer grade or patch geometry.

A commercially useful portfolio should combine formulation claims with process, device, packaging, and method-of-use claims. Patent-term management is important because a late-filed formulation patent may expire shortly after approval unless the product generates meaningful differentiation.

What licensing deals could create value?

Licensing opportunities are most credible in four areas:

• Medical-grade pressure-sensitive adhesive technology.
• Permeation-enhancer systems with human safety data.
• Flexible backing and liner technologies.
• Contract manufacturing capacity for solvent coating and pouching.

A license is more valuable when it includes regulatory support, freedom-to-operate rights, supplier qualification, and manufacturing know-how. A patent-only license may not solve the principal development risk, which is reproducible patch performance at commercial scale.

Potential deal structures include an upfront payment for platform access, development milestones tied to bioequivalence or approval, royalties on net sales, and supply commitments for proprietary adhesive or liner materials.

What generic launch risks exist for norelgestromin and ethinyl estradiol?

Generic entry risk is moderate from a legal perspective but high from a technical and supply perspective.

Risk	Likely impact
Adhesion failure	Product complaints, recalls, loss of substitution
Pharmacokinetic divergence	ANDA deficiency or additional studies
Skin irritation	Lower persistence and higher discontinuation
Limited manufacturing capacity	Supply shortages and delayed launch
Active crystallization	Release failure during stability testing
Packaging defects	Moisture ingress and shelf-life loss
Patent litigation	Launch delay or settlement restrictions
Payer resistance	Lower realized price despite approval

The most credible generic launch scenario is a conventional patch with equivalent active ingredients and comparable delivery performance. The most disruptive scenario is a smaller, better-adhering patch with lower estrogen exposure, but that product would face greater clinical and regulatory costs.

How does norelgestromin and ethinyl estradiol compare with other contraceptive patches?

Product	Active ingredients	Dosing interval	Main differentiation
Xulane	Norelgestromin and ethinyl estradiol	Weekly for three weeks	Established product, generic competition
Ortho Evra	Norelgestromin and ethinyl estradiol	Weekly for three weeks	Original branded product
Twirla	Levonorgestrel and ethinyl estradiol	Weekly for three weeks	Different progestin and lower nominal estrogen delivery
Oral contraceptives	Varies	Daily	Broadest product selection
Vaginal rings	Varies	Monthly or extended	Less visible delivery system
Long-acting methods	Varies	Months to years	Highest adherence advantage

Twirla is not a direct generic equivalent to Xulane because it uses levonorgestrel rather than norelgestromin.[5] The principal competitive comparison is therefore delivery-system performance, estrogen exposure, tolerability, and user preference.

Key Takeaways

• Norelgestromin and ethinyl estradiol patches are polymeric drug-in-adhesive systems, not simple dosage-form products.
• Polyisobutylene, polybutene, crospovidone, polyester materials, and release-liner components drive adhesion, release, stability, and usability.
• The best commercial opportunities are improved adhesion, smaller patch size, better skin tolerability, reduced estrogen exposure, and longer wear duration.
• Core active-ingredient exclusivity is mature; future value depends on formulation, device, manufacturing, and process patents.
• Generic entry is technically more difficult than a conventional oral contraceptive ANDA because adhesion and transdermal delivery must remain comparable.
• Twirla is a competing hormonal patch but is not an equivalent product because it contains levonorgestrel rather than norelgestromin.
• A strong lifecycle portfolio should combine composition, patch architecture, manufacturing, packaging, and method-of-use claims.

FAQs

Can a new adhesive create patent protection for an old contraceptive patch?

Yes. A novel adhesive composition can support patent protection if it has a non-obvious formulation and produces measurable advantages such as improved seven-day adhesion, lower irritation, or a distinct release profile.

Are transdermal contraceptive patches eligible for biosimilar approval?

No. Biosimilar pathways apply to biological products. Norelgestromin and ethinyl estradiol patches are chemically synthesized drug-device products and are evaluated through generic-drug and product-specific regulatory pathways.

What excipient is most important for patch performance?

The pressure-sensitive adhesive system is usually the most important. It controls skin contact, drug diffusion, residual drug, release consistency, and user experience.

Can a smaller norelgestromin and ethinyl estradiol patch be approved as a generic?

Potentially, but a smaller patch may not meet the same product-performance requirements as the reference patch. Changes in area, drug loading, flux, adhesion, or exposure can require additional regulatory evidence.

Is a formulation patent enough to prevent generic entry?

Usually not by itself. A formulation patent can create a barrier, but generic sponsors may design around the claim. The strongest protection combines formulation, device, manufacturing, packaging, and method-of-use patents.

References

1. U.S. Food and Drug Administration. (2023). Xulane (norelgestromin and ethinyl estradiol) transdermal system prescribing information.
2. DailyMed. (2023). Xulane: Norelgestromin and ethinyl estradiol patch, extended release. National Library of Medicine.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2022). Abbreviated new drug application submissions: Refuse-to-receive standards.
5. U.S. Food and Drug Administration. (2023). Twirla (levonorgestrel and ethinyl estradiol) transdermal system prescribing information.
6. U.S. Food and Drug Administration. (2019). Transdermal and topical delivery systems: Product development and quality considerations.